DBV Technologies | DBVT - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.37M 14.6M 2025-09
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Esperion Therapeutics USD 67.66M 3.6M 2024-09
Galectin Therapeutics USD 11.29M 1.64M 2024-06
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12